Top-Rated StocksTop-RatedNASDAQ:PLRX Pliant Therapeutics (PLRX) Stock Price, News & Analysis → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Free PLRX Stock Alerts $13.81 0.00 (0.00%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$13.33▼$14.0050-Day Range$11.81▼$16.3952-Week Range$11.21▼$24.74Volume487,214 shsAverage Volume346,132 shsMarket Capitalization$833.10 millionP/E RatioN/ADividend YieldN/APrice Target$45.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Pliant Therapeutics alerts: Email Address Pliant Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside230.7% Upside$45.67 Price TargetShort InterestBearish12.52% of Shares Sold ShortDividend StrengthN/ASustainability-0.73Upright™ Environmental ScoreNews Sentiment0.15Based on 33 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($3.39) to ($3.67) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.07 out of 5 starsMedical Sector177th out of 925 stocksPharmaceutical Preparations Industry71st out of 430 stocks 4.5 Analyst's Opinion Consensus RatingPliant Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePliant Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Pliant Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted12.52% of the outstanding shares of Pliant Therapeutics have been sold short.Short Interest Ratio / Days to CoverPliant Therapeutics has a short interest ratio ("days to cover") of 21.8, which indicates bearish sentiment.Change versus previous monthShort interest in Pliant Therapeutics has recently decreased by 0.92%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldPliant Therapeutics does not currently pay a dividend.Dividend GrowthPliant Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePliant Therapeutics has received a 74.73% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Pliant Therapeutics is -0.73. Previous Next 1.8 News and Social Media Coverage News SentimentPliant Therapeutics has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 33 news articles for Pliant Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for PLRX on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 8 people have added Pliant Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pliant Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.60% of the stock of Pliant Therapeutics is held by insiders.Percentage Held by Institutions97.30% of the stock of Pliant Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Pliant Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Pliant Therapeutics are expected to decrease in the coming year, from ($3.39) to ($3.67) per share.Price to Book Value per Share RatioPliant Therapeutics has a P/B Ratio of 1.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Pliant Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About Pliant Therapeutics Stock (NASDAQ:PLRX)Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.Read More PLRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PLRX Stock News HeadlinesMay 11, 2024 | americanbankingnews.comPliant Therapeutics, Inc. (NASDAQ:PLRX) to Post Q2 2024 Earnings of ($0.82) Per Share, HC Wainwright ForecastsMay 9, 2024 | americanbankingnews.comHC Wainwright Reiterates Buy Rating for Pliant Therapeutics (NASDAQ:PLRX)May 11, 2024 | Crypto 101 Media (Ad)Tech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. May 9, 2024 | americanbankingnews.comPliant Therapeutics (NASDAQ:PLRX) PT Raised to $48.00May 9, 2024 | americanbankingnews.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Forecasted to Post Q2 2024 Earnings of ($0.81) Per ShareMay 9, 2024 | americanbankingnews.comPliant Therapeutics (NASDAQ:PLRX) Rating Reiterated by Needham & Company LLCMay 9, 2024 | americanbankingnews.comRoyal Bank of Canada Lowers Pliant Therapeutics (NASDAQ:PLRX) Price Target to $45.00May 9, 2024 | americanbankingnews.comCitigroup Lowers Pliant Therapeutics (NASDAQ:PLRX) Price Target to $44.00May 11, 2024 | Crypto 101 Media (Ad)Tech GIANT’s Plans to Revolutionize Crypto…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. May 8, 2024 | markets.businessinsider.comPliant Therapeutics: Advancing Trials and Diversifying Pipeline Justify Buy RatingMay 8, 2024 | markets.businessinsider.comBuy Rating for Pliant Therapeutics: Promising Trials and Strategic Shifts Signal Growth PotentialMay 8, 2024 | finance.yahoo.comPliant Therapeutics First Quarter 2024 Earnings: US$0.78 loss per share (vs US$0.67 loss in 1Q 2023)May 7, 2024 | markets.businessinsider.comBullish Outlook: Buy Rating on Pliant Therapeutics Amid Strong Clinical Trials and Solid FinancialsMay 7, 2024 | markets.businessinsider.comBuy Rating Justified by Pliant Therapeutics’ Promising Pipeline and Financial PrudenceMay 7, 2024 | msn.comThese Analysts Revise Their Forecasts On Pliant Therapeutics Following Q1 EarningsMay 7, 2024 | tmcnet.comPliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™May 7, 2024 | finance.yahoo.comPliant Therapeutics Announces Upcoming Presentations at the European Association for the Study of the Liver International Liver Congress™May 6, 2024 | investorplace.comPLRX Stock Earnings: Pliant Therapeutics Misses EPS for Q1 2024May 6, 2024 | globenewswire.comPliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 1, 2024 | globenewswire.comPliant Therapeutics to Participate in Upcoming Investor EventsApril 9, 2024 | investing.comPliant Therapeutics Inc (PLRX)April 2, 2024 | globenewswire.comPliant Therapeutics to Participate in Upcoming Investor EventsMarch 27, 2024 | globenewswire.comPliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International ConferenceMarch 17, 2024 | finance.yahoo.comPLRX Oct 2024 30.000 callMarch 16, 2024 | finance.yahoo.comPLRX Oct 2024 7.500 putMarch 12, 2024 | finanznachrichten.dePliant Therapeutics, Inc.: Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary FibrosisMarch 12, 2024 | globenewswire.comPliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary FibrosisSee More Headlines Receive PLRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pliant Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today5/11/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PLRX CUSIPN/A CIK1746473 Webpliantrx.com Phone650-481-6770FaxN/AEmployees158Year FoundedN/APrice Target and Rating Average Stock Price Target$45.67 High Stock Price Target$63.00 Low Stock Price Target$36.00 Potential Upside/Downside+230.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-161,340,000.00 Net MarginsN/A Pretax Margin-68,847.98% Return on Equity-35.08% Return on Assets-31.78% Debt Debt-to-Equity Ratio0.07 Current Ratio16.12 Quick Ratio17.72 Sales & Book Value Annual Sales$1.58 million Price / Sales527.31 Cash FlowN/A Price / Cash FlowN/A Book Value$7.25 per share Price / Book1.90Miscellaneous Outstanding Shares60,330,000Free Float56,948,000Market Cap$833.16 million OptionableOptionable Beta1.19 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Bernard Coulie M.B.A. (Age 57)M.D., Ph.D., President, CEO & Director Comp: $1.06MDr. Keith Lamont Cummings M.B.A. (Age 47)M.D., Chief Financial Officer Comp: $662.34kMr. Mike Ouimette J.D. (Age 51)General Counsel & Corporate Secretary Comp: $591.05kMr. Johannes P. Hull (Age 49)Chief Business Officer Comp: $631.64kDr. Éric Lefebvre M.D. (Age 60)Chief Medical Officer Comp: $763.49kDr. Rik DerynckScientific Founder & Member of Scientific Advisory BoardMr. Dean Sheppard M.D.Scientific Founder & Member of Scientific Advisory BoardMr. Bill DeGrado Ph.D.Scientific Founder & Member of Scientific Advisory BoardMr. Hal Chapman M.D.Scientific Founder & Member of Scientific Advisory BoardMr. Craig D. MuirInterim Chief Technology OfficerMore ExecutivesKey CompetitorsTango TherapeuticsNASDAQ:TNGXEvolusNASDAQ:EOLSLongboard PharmaceuticalsNASDAQ:LBPHZentalis PharmaceuticalsNASDAQ:ZNTLALX OncologyNASDAQ:ALXOView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 412,486 shares on 5/10/2024Ownership: 5.767%Russell Investments Group Ltd.Sold 13,387 shares on 5/8/2024Ownership: 0.077%ProShare Advisors LLCBought 1,203 shares on 5/8/2024Ownership: 0.024%SG Americas Securities LLCBought 7,212 shares on 5/7/2024Ownership: 0.012%China Universal Asset Management Co. Ltd.Bought 4,652 shares on 4/29/2024Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions PLRX Stock Analysis - Frequently Asked Questions Should I buy or sell Pliant Therapeutics stock right now? 10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pliant Therapeutics in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PLRX shares. View PLRX analyst ratings or view top-rated stocks. What is Pliant Therapeutics' stock price target for 2024? 10 brokers have issued 1 year price objectives for Pliant Therapeutics' stock. Their PLRX share price targets range from $36.00 to $63.00. On average, they expect the company's share price to reach $45.67 in the next twelve months. This suggests a possible upside of 230.7% from the stock's current price. View analysts price targets for PLRX or view top-rated stocks among Wall Street analysts. How have PLRX shares performed in 2024? Pliant Therapeutics' stock was trading at $18.11 at the start of the year. Since then, PLRX stock has decreased by 23.7% and is now trading at $13.81. View the best growth stocks for 2024 here. When is Pliant Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our PLRX earnings forecast. How were Pliant Therapeutics' earnings last quarter? Pliant Therapeutics, Inc. (NASDAQ:PLRX) posted its quarterly earnings results on Tuesday, November, 9th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.69) by $0.06. The business earned $1.61 million during the quarter, compared to analyst estimates of $2.50 million. What ETFs hold Pliant Therapeutics' stock? ETFs with the largest weight of Pliant Therapeutics (NASDAQ:PLRX) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE). What other stocks do shareholders of Pliant Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pliant Therapeutics investors own include Pfizer (PFE), CrowdStrike (CRWD), Trevena (TRVN), AbbVie (ABBV), Abbott Laboratories (ABT), Archer-Daniels-Midland (ADM), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD) and Applied DNA Sciences (APDN). When did Pliant Therapeutics IPO? Pliant Therapeutics (PLRX) raised $90 million in an initial public offering on Wednesday, June 3rd 2020. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and Piper Sandler acted as the underwriters for the IPO and Needham & Company was co-manager. Who are Pliant Therapeutics' major shareholders? Pliant Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.77%), Mass General Brigham Inc (0.48%), Russell Investments Group Ltd. (0.08%), HighMark Wealth Management LLC (0.07%), ProShare Advisors LLC (0.02%) and China Universal Asset Management Co. Ltd. (0.02%). Insiders that own company stock include Bernard Coulie, Eric Lefebvre, Hans Hull, Keith Lamont Cummings, Matthew Dunnigan and Mike Ouimette. View institutional ownership trends. How do I buy shares of Pliant Therapeutics? Shares of PLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PLRX) was last updated on 5/11/2024 by MarketBeat.com Staff From Our PartnersThe Crypto 9-5 Escape PlanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsObama’s Forever Term [exposed]Porter & CompanyMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetryForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pliant Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.